The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Phase II Study of Induction Chemotherapy (IND CT) with CPT-11 and Cisplatin Followed by Thoracic Radiation (TRT) Combined with Weekly CPT-11 in Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC).
 
Thierry Andre
Honoraria - Baxter; BAYER; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD Oncology; Novartis; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche/Genentech
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Bayer
Speakers' Bureau - Lilly; Roche
Research Funding - Sanofi
 
Mark Wong
Consulting or Advisory Role - Baxalta
Speakers' Bureau - Sirtex Medical
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Heinz-Josef Lenz
Honoraria - Bristol-Myers Squibb; Merck; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche
Research Funding - Bristol-Myers Squibb; EMD Serono; Merck; Roche; Taiho Pharmaceutical
 
Fabio Gelsomino
No Relationships to Disclose
 
Massimo Aglietta
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Genentech/Roche; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Genentech/Roche; Novartis; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Andrew G Hill
Employment - Tasman Oncology
Leadership - Tasman Oncology
Stock and Other Ownership Interests - Tasman Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Michael B. Sawyer
Honoraria - Baxter; Bristol-Myers Squibb; Celgene; Fresenius Kabi; LEO Pharma; Novartis; nutricia; pfizer; Sanofi; Shire
Consulting or Advisory Role - Celgene; LEO Pharma; Nutricia; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - My lab discovered that all the competitive tyrosine kinase inhibitors such as sunitinib and gefitinib have additional pharmacological properties. This additional pharmacologic property causes intestinal epithelial cells to active their chloride channels l
Travel, Accommodations, Expenses - Amgen; LEO Pharma; Novartis Canada Pharmaceuticals Inc; Nutricia; pfizer
 
Alain Hendlisz
Research Funding - Bayer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Roche
 
Bart Neyns
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis
Speakers' Bureau - Novartis
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Novartis; Pfizer; Roche
 
Magali Svrcek
No Relationships to Disclose
 
Rebecca Anne Moss
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Bayer
Consulting or Advisory Role - Taiho Pharmaceutical
 
Jean-Marie Ledeine
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Z. Alexander Cao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Shital Kamble
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; Navire
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; EMD Serono; Genentech; Guardant Health (Inst); Karyopharm Therapeutics; Merck; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Merrimack; Roche/Genentech
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; MedImmune; Merck; Roche